MEDICINA
Departamento
Juan Antonio
Pineda Vergara
Publicaciones en las que colabora con Juan Antonio Pineda Vergara (34)
2024
-
Long or complicated mpox in patients with uncontrolled HIV infection
Journal of Medical Virology, Vol. 96, Núm. 3
2021
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study
HIV Medicine, Vol. 22, Núm. 9, pp. 867-876
-
Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response
AIDS (London, England), Vol. 35, Núm. 13, pp. 2119-2127
2020
-
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study
The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573
-
How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain
HIV Medicine, Vol. 21, Núm. 2, pp. 128-134
2019
-
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world
Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888
-
Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients
AIDS, Vol. 33, Núm. 2, pp. 269-278
-
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort
PLoS ONE, Vol. 14, Núm. 8
2018
-
Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients
AIDS, Vol. 32, Núm. 11, pp. 1423-1430
-
Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis
PLoS ONE, Vol. 13, Núm. 7
2016
-
Hepatic safety of rilpivirine/emtricitabine/tenofovir disoproxil fumarate fixed-dose single-tablet regimen in HIV-infected patients with active hepatitis C virus infection: The hepatic study
PLoS ONE, Vol. 11, Núm. 5
-
MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression
PLoS ONE, Vol. 11, Núm. 5
2015
-
Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes
Antiviral Research, Vol. 120, pp. 79-84
2014
-
Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting
HIV Medicine, Vol. 15, Núm. 7, pp. 417-424
-
Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions
PLoS ONE, Vol. 9, Núm. 12
-
Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes
International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6
2012
-
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial
Journal of Infectious Diseases, Vol. 206, Núm. 6, pp. 961-968
2011
-
Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients
AIDS, Vol. 25, Núm. 6, pp. 761-766
-
Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100mg once daily in HIV/Hepatitis C Virus-Coinfected Patients
AIDS Patient Care and STDs, Vol. 25, Núm. 7, pp. 395-402
2009
-
Efficacy and safely of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression
Clinical Infectious Diseases, Vol. 49, Núm. 8